MPMichael W. Parsons

Michael W. Parsons

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael W. Parsons has a total of 125 co-authors. Here are the top co-authors by number of shared publications:

  • Jorg Dietrich

    Department of Neuro-Oncology, Massachusetts General Hospital , Boston, MA

    5 shared publications
  • Jorg Dietrich

    Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Boston, Massachusetts, United States

    4 shared publications
  • Emiliano Santarnecchi

    Precision Neuromodulation Program & Network Control Laboratory, Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    2 shared publications
  • Giuliana V Zarrella

    Department of Psychiatry, Psychology Assessment Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

    2 shared publications
  • Giuliana V. Zarrella

    Pappas Center for Neuro-Oncology, Mass General Brigham, Boston, USA

    2 shared publications
  • Giuliana V. Zarrella

    Virginia Commonwealth University , Department of Psychology

    2 shared publications

Latest Publications

  • C-SMART – Cognitive Strategies, Mindfulness, and Rehabilitation Therapy: Development and Phase I Trial of a Neuropsychological Intervention in Neuro-Oncology

    by Sarah E Braun, Ashlee R Loughan, Autumn Lanoye, Giuliana V Zarrella, Brighton Payne, Amber Fox, Michael W Parsons, William C Broaddus, F Gerard Moeller, Oxana Palesh

    Background: Adult patients with primary brain tumors experience significant cognitive sequelae yet remain underrepresented in behavioral intervention research. We present the development and preliminary evaluation of C-SMART (Cognitive Strategies, Mindfulness, and Rehabilitation Therapy), an integrated cognitive rehabilitation and mindfulness-based intervention designed for patients with primary brain tumor and mild cognitive decline. Stakeholder input was systematically incorporated prior to launching a single-arm pilot trial assessing feasibility and acceptability. Methods: Following the NIH ORBIT Model, Phase Ia convened two advisory boards: one comprised of brain tumor patients and caregivers (n=4) and another of neuro-oncology professionals (n=5) to inform C-SMART intervention development. Next, feasibility and acceptability were investigated in a single-arm Phase Ib design (n = 18 patients; n = 14 caregivers), with an exploratory aim of assessing preliminary signal change on neurocognitive performance and patient-reported outcomes. Results: Phase Ia results supported an individually tailored neuropsychological intervention integrating mindfulness training and caregiver involvement to address patient-centered goals. Phase Ib results met all primary aims of feasibility and acceptability, with rates of enrollment, retention, and satisfaction exceeding established benchmarks. Caregiver involvement was robust, with reported benefit. Qualitative data from exit interviews supported the benefits of C-SMART on self-efficacy and interpersonal functioning with recommendations to increase caregiver involvement. Exploratory outcomes demonstrated signal change, supporting progression to a Phase II trial. Conclusions: C-SMART is the first consensus-supported, individualized, mindfulness-based, neuropsychological intervention in neuro-oncology. Evidence provides strong support for feasibility and acceptability of the tailored intervention with key recommendations for optimization, including increased structure for caregiver involvement and self-efficacy outcome measurement.

  • The neuropsychological impacts of supratotal glioma resection: A systematic review

    by James Tanner McMahon, Diego Alejandro Hernandez Langarica, Mohammad Keshtkar, Stephanie Friree Ford, Brian Nahed, Jorg Dietrich, Michael Parsons

    Background: Supratotal resection (SpTR) has emerged as a compelling surgical target for gliomas, with a strong signal toward improved survival. However, the balance between resections extending into tumor-infiltrated normal brain and preservation of higher-order cognitive function remains poorly defined. This systematic review aims to characterize formal neuropsychological (NP) outcomes following glioma SpTR. Methods: A PRISMA-adherent systematic search was conducted across six electronic databases. Inclusion criteria required patients with WHO Grade 2-4 gliomas undergoing SpTR with standardized NP assessment. Quality was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklists. Results: Fifty-five studies reported SpTR for glioma, but only 11 (20%) utilized formal NP testing as an outcome. 80% of studies omitting NP testing focused exclusively on high-grade glioma (HGG). Cognitive data was available from 2 studies in HGG and 9 studies in LGG. Early post-operative cognitive declines were reported in 55.5% of extractable cohorts, predominantly in the domains of executive function and memory/learning. The majority of these studies report cognitive recovery after 3-6 months. Long-term permanent cognitive morbidity was indeed very low (∼1%), but critical appraisal revealed a high risk of bias. Conclusions: While current evidence suggests SpTR is functionally safe, these findings are limited by high risk of bias and a lack of comparative controls. A reporting gap remains in functional-cognitive outcomes after HGG surgery. Standardized, anatomically anchored NP testing will be essential to validate the “onco-functional balance” of supratotal margins.

  • Open Access

    Functional brain network alterations linked to cancer-related cognitive impairment in breast cancer patients

    by Alberto Benelli, Julianne Reilly, Jorge Ortega-Márquez, Michael Parsons, Jorg Dietrich, Giulia Sprugnoli, Felipe Fregni, Emiliano Santarnecchi

    Background: Life expectancy for cancer patients has improved due to new therapies, but many survivors experience long-lasting side effects, including cancer-related cognitive impairment (CRCI). CRCI symptoms—such as difficulties with attention, memory, processing speed, fatigue, and concentration—can persist for years post-treatment. While clinical evidence of CRCI exists, its underlying mechanisms and neural correlates remain unclear. This study aimed to identify functional brain networks associated with CRCI in breast cancer (BC) patients using structural and functional neuroimaging data. Methods: We reviewed studies on CRCI-related brain changes assessed via diffusion tensor imaging (DTI, n = 282), voxel-based morphometry (VBM, n = 177), and functional MRI (fMRI, n = 328). Using the Yeo 7-network resting-state functional atlas, we evaluated the overlap between CRCI-related brain alterations and known functional networks. Overlapping percentages were calculated, and statistical independence tests assessed associations between CRCI and specific networks. Results: Based on inclusion criteria, six DTI, six VBM, and ten fMRI studies were selected. Chi-square analyses revealed significant associations between CRCI-related changes and several networks: the Dorsal Attention Network (DAN, χ2 = 17.71, P = .0001), Default Mode Network (DMN, χ2 = 21.08, P = .0000002), Frontoparietal Network (FPN, χ2 = 110.63, P = .000002), and Ventral Attention Network (VAN, χ2 = 8.203, P = .01). Conclusions: Findings highlight network-specific alterations linked to CRCI symptoms in breast cancer survivors. These results enhance understanding of CRCI and may guide targeted therapeutic strategies.

  • Open Access

    Cognitive dysfunction associated with cellular immunotherapy for cancer

    by Anna G Hauswirth, Michael W Parsons, Jorg Dietrich

    Immunotherapies engage the individual’s immune system to fight both hematologic and solid malignancies and have led to durable clinical responses for many patients. A subset of immunotherapies, including T cell engagers (TCEs) and chimeric antigen receptor T-cell therapies (CAR-T), use T cell mediated mechanisms to induce cancer cell death. These therapies can be very effective against the cancer while also causing significant systemic and neurologic toxicity, including cognitive dysfunction. Here, we provide a review on the existing and emerging literature describing the acute, subacute, and potential long-term effects of CAR-T cells and other T-cell-engaging therapies on cognition. While the acute effects on cognition, including immune effector cell-associated neurotoxicity syndrome are becoming better characterized, there is mixed data on the long-term subjective and objective cognitive outcomes after T-cell-based immunotherapies. Further research is needed, especially as these promising and effective therapies become more commonly used for both hematologic and solid malignancies.


  • Brain Tumors

    by Jennifer L. Nosker, Michael W. Parsons

    This chapter examines the dynamic nature of cognition in brain tumor survivors, including the extent and severity of cognitive impairment and the potential for reversibility of symptoms. As cognitive outcomes depend on a complex interplay of factors, this chapter reviews the most common types of primary and secondary tumors, their neuropsychological sequelae, and the potential for reversibility based on brain tumor characteristics (tumor type, size, growth rate). Different antitumor treatments (surgery, radiation, systemic therapy) and their effects on cognition are also reviewed, with an emphasis on approaches that aim to preserve neurocognitive functioning and quality of life. Finally, a case involving a patient with a meningioma is presented to demonstrate the improvement in cognitive symptoms following treatment.

  • Factors associated with cognitive impairment in long-term IDH-mutant glioma survivors

    by Tyler A. Lanman, Hana Gross, Caylin M. Faria, Julie J. Miller, Daniel P. Cahill, Helen A. Shih, Giuliana V. Zarrella, Jorg Dietrich, Michael W. Parsons

    Purpose Cognition is a critical patient-relevant outcome in IDH-mutant (IDHm) glioma; however, there is a limited understanding of long-term neurocognition in this population and its implications for quality of life (QoL), especially in the modern era of molecular classification. We sought to evaluate long-term neurocognitive outcomes in patients with IDHm glioma. Methods We identified a cohort of adult patients with molecularly defined IDHm glioma treated at Massachusetts General Hospital who underwent neuropsychological assessment 3 + years from initial diagnosis. Results This cohort included 63 patients with pathologically proven IDH-mutant gliomas (46% female, median age 45, median 16 years of education, and underwent testing a median 7 years from diagnosis). 40% had oligodendroglioma, and 60% had astrocytoma, with 44, 49, and 6% WHO grade 2, 3, and 4 tumors, respectively. Cognitive impairment (defined as z-score ≤ -1.5 on at least 2 tests in different cognitive domains) was present in 30 patients (48%) and was associated with higher grade (p = 0.03 for grade 3 vs. 2), L-sided laterality (p = 0.02), female sex (p = 0.04), less education (p = 0.02), older age at testing (p = 0.03), longer disease duration (p = 0.01), prior chemotherapy (p = 0.03), and prior radiotherapy (p = 0.03). Cognitive impairment predicted lower scores on a cognitive-focused QoL measure (p < 0.001). This cohort was more impaired compared to a previously reported cohort who were tested at disease onset. Conclusion In this population of long-term survivors of IDHm glioma, neurocognitive deficits were common, occurred more frequently than in a comparable newly diagnosed cohort, related to QoL, and associated with clinical and demographic factors. These findings emphasize the need for future research on interventions to support these patients’ neurocognitive abilities and QoL.


  • Open Access

    Long-Term Cognitive Outcomes in Adult Patients Receiving Chimeric Antigen Receptor T-Cell Therapies

    by Anna Barata, P. Connor Johnson, Tejaswini M. Dhawale, Richard A. Newcomb, Hermion L. Amonoo, Mitchell W. Lavoie, Dagny Vaughn, Kyle Karpinski, Bridget Coffey, Giuliana V. Zarrella, et al.


  • Neurocognitive Changes

    by Alissa M. Butts, Jane H. Cerhan, Michael W. Parsons, Paul D. Brown

  • Brain volume loss after cranial irradiation: a controlled comparison study between photon vs proton radiotherapy for WHO grade 2–3 gliomas

    by Melissa M. Gardner, Sebastian F. Winter, Franziska Stahl, Elizabeth R. Gerstner, Helen A. Shih, Janet Sherman, Jorg Dietrich, Michael W. Parsons

    Purpose Radiation therapy (RT) is an integral treatment component in patients with glioma but associated with neurotoxicity. Proton RT (PRT), as compared with photon RT (XRT), reduces excess radiation to nontarget tissue. We used a retrospective method to evaluate brain imaging metrics of neurotoxicity after treatment with PRT and XRT for glioma. Methods We analyzed brain volume change in thirty-four patients with WHO grade 2–3 gliomas treated with either PRT (n = 17) or XRT (n = 17). Both groups were carefully matched by demographic/clinical criteria and assessed longitudinally for two years post-radiotherapy. Brain volume change was measured as ventricular volume expansion in the tumor free hemisphere (contralateral to RT target) as a proxy indicator of brain volume loss. We further assessed the impact of volumetric changes on cognition in PRT patients, who completed neuropsychological testing as part of an outcome study. Results We found significant ventricular volume increases in the contralesional hemisphere in both groups at two years post-RT (F(1, 31) = 18.45, p < 0.000, partial η2 = 0.373), with greater volume change observed in XRT (26.55%) vs. PRT (12.03%) (M = 12.03%, SD = 16.26; F(1,31) = 4.26, p = 0.048, partial η2 = 0.121). Although, there was no group-level change on any cognitive test in PRT treated patients, individual changes on cognitive screening, working memory, processing speed and visual memory tasks correlated with contralesional brain volume loss. Conclusion This study suggests progressive brain volume loss following cranial irradiation, with greater severity after XRT vs. PRT. Radiation-induced brain volume loss appears to be associated with measurable cognitive changes on an individual level. Prospective studies are warranted to validate these findings and their impacts on long-term cognitive function and quality of life. An improved understanding of the structural and functional consequences of cranial radiation is essential to develop neuroprotective strategies.


  • Exploring Novel Therapeutic Avenues for Chemotherapy-Related Cognitive Impairment

    by Jorg Dietrich, Michael W. Parsons, Emiliano Santarnecchi

    Many patients with cancer are at risk of developing cognitive symptoms that often become evident during or after cancer-directed therapy and may have difficulties with attention, concentration, multitasking, executive function, and memory. Despite recent advances in identifying potential molecular and cellular mechanisms underlying cancer and chemotherapy-related cognitive impairment, there is generally a lack of effective treatment strategies, and the development of novel therapeutic interventions represents a major unmet medical need in clinical practice. A recent study by Kim and colleagues suggests that multisensory 40-Hz gamma entrainment using sensory stimuli with combined visual and auditory stimuli is associated with powerful neuroprotective effects in mouse models of cisplatin- or methotrexate-induced “chemobrain.” Although the study has some limitations and successful interventions in animal models have often failed to translate into clinical practice, this noninvasive treatment modality has shown promise in preserving brain structure and function and could be tested in patients with cancer who are at risk of cognitive decline.